1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,350 | 3,538 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375, ORAL KRAS G12D INHIBITOR, ADVANCES INTO A PHASE II STUDY EVALUATING MONOTHERAPY AND COMBINATION REGIMENS ... | 1 | HKEx | ||
| 21.08. | GENFLEET-B Interim Loss Narrows to RMB220 million | 1 | AASTOCKS | ||
| 21.08. | GENFLEET-B (02595): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 20.08. | GENFLEET-B Initiates Phase II Study for Two Pancreatic Cancer Combination Therapies of GFH375 | 1 | AASTOCKS | ||
| 20.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 ADVANCES INTO A NOVEL PHASE II STUDY FEATURING TWO FIRST-IN-WORLD COMBINATION THERAPIES FOR PANCREATIC ... | 2 | HKEx | ||
| 10.08. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT WORLD'S FIRST REGISTRATIONAL PHASE III STUDY FOR ORAL KRAS G12D INHIBITOR IN NSCLC ADVANCES, AS FIRST PATIENT ... | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.08. | GENFLEET-B (02595): DATE OF BOARD MEETING | 1 | HKEx | ||
| 17.07. | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 17.07. | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 17.07. | GENFLEET-B (02595): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 15.07. | GENFLEET-B (02595): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 29.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE ON THE MARKET | 2 | HKEx | ||
| 02.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 MONOTHERAPY DATA PRESENTED AT 2026 ASCO ORAL SESSION: WORLD'S FIRST DEDICATED DATA OF A RAS INHIBITOR ... | 1 | HKEx | ||
| 01.06. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRELIMINARY PHASE I DATA OF GFS202A FOR CACHEXIA PRESENTED IN POSTER SESSION OF 2026 ASCO ANNUAL MEETING, FEATURING ... | 1 | HKEx | ||
| 11.05. | GENFLEET-B (02595): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 11, 2026 | 1 | HKEx | ||
| 28.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT STATEMENT ON THE PROPRIETARY INTELLECTUAL PROPERTY STATUS OF GFH276, A PAN RAS (ON) INHIBITOR | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 11 MAY 2026 | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 17.04. | GENFLEET-B (02595): 2025 ANNUAL REPORT | 1 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Personalentscheidungen / Vorstand/Strategische Unternehmensentscheidung
QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Merck, Vidac Pharma, Moderna - Neue Krebswaffen elektrisieren die Börse | Ein Durchbruch in der Krebsforschung versetzte die Börse in der vergangenen Woche in Euphorie. Eine personalisierte mRNA-Therapie hat erstmals in einer großen Phase-3-Studie entscheidende Ziele erreicht... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
GENFLEET THERAPEUTICS SHANGHAI INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,448 Euro und damit +0,12 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.